ReviewCureus2026
The Gluco-Vascular Injury Axis in Diabetic Cardiovascular Dysfunction: A Narrative Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiovascular dysfunction arises from a progressive metabolic-vascular-myocardial injury pathway rather than from hyperglycemia alone. In this review, the "gluco-vascular injury axis" is used as a proposed conceptual framework describing how diabetes-related metabolic stress promotes endothelial dysfunction, vascular injury, microvascular impairment, myocardial remodeling, and heart failure. Chronic hyperglycemia, insulin resistance, dyslipidemia, oxidative stress, inflammation, AGE-RAGE (advanced glycation end products-receptor for advanced glycation end products) signaling, mitochondrial impairment, arterial stiffness, and coronary microvascular dysfunction contribute to fibrosis, diastolic dysfunction, and heart failure. Because these mechanisms are often discussed separately, the primary clinical message can become obscured. This narrative review synthesizes mechanistic, experimental, and clinical evidence to organize these processes into a clinically interpretable continuum. The novelty of this review lies in integrating diabetic cardiomyopathy, atherosclerosis, endothelial dysfunction, and coronary microvascular disease into one metabolic-vascular-myocardial framework, with endothelial dysfunction positioned as the transition point between glucose-lipid stress and cardiovascular injury. It was not designed as a systematic review and did not use formal search, screening, or meta-analytic methods. The review highlights metabolic triggers, endothelial injury, inflammatory amplification, macrovascular disease, microvascular dysfunction, mitochondrial redox imbalance, and diabetic cardiomyopathy. The key takeaway is that cardiovascular protection in diabetes may need to address the entire gluco-vascular injury process through a combination of metabolic, endothelial, inflammatory, mitochondrial, microvascular, and myocardial protective strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.